The ASX edged lower at lunch as oil rose on Black Sea strikes, miners slid and IperionX copped a sharp post-short seller ...

Genetics Signatures says US sales of the company's Easyscreen diagnostics have disappointed, but a revamped strategy should ...

Strong patient demand and expanding trial sites are helping Paradigm progress its long-awaited phase III knee OA study.

Backed by government and industry partners, Micro-X is pushing its cold-cathode X-ray tech toward commercial readiness.

Tylah Tully looks at Vertex Minerals and the increasingly alluring gold grades coming out of its Reward gold mine in New ...

Rare earths and mineral sands hopeful Ark Mines wants to ride a wave of government support to production as soon as 2027.

Salary sacrificing promises instant tax savings and a bigger nest egg, but it seems to have lost its lustre. Here’s why.

Copper comes at a premium, and Garimpeiro likes the upside in one of the largest deposits owned by a junior developer.

It’s no easy gig analysing share prices and company performance but somebody’s got to do it. Two experts give us their ...

Gold prices have hit a wall after a massive run-up, but miners are well placed to make money and experts say fundamentals are ...

The Reserve Bank might have posted its last rates cut in the current easing cycle, but the impact on shares might be less ...

The ASX healthcare sector finished the week in a steady state, despite ripple effects of a sharp sell-off on Wall Street.